The dihydropteroate synthase (DHPS) gene from Pneumocystis carinii isolated from non-human primates was ampli ed using a polymerase chain reaction (PCR) and sequenced to analyse point mutations associated with sulfa resistance. P. carinii DHPS gene ampli cation was obtained from eight lung samples from ve New World primate species and one Old World primate species. None of the animals had been exposed to sulfa drugs and only the wild-type P. carinii DHPS sequence at codons 55 and 57 was observed. These data support the hypothesis that high rates of DHPS mutants in P. carinii f. sp. hominis have arisen with increased use of sulfa drugs for P. carinii pneumonia prophylaxis.
Introduction
Cotrimoxazole (sulfamethoxazole and trimethoprim) remains the most widely used drug for both the treatment and long-term prophylaxis of Pneumocystis carinii pneumonia (PCP) in HIV-infected individuals and other immunocompromised patients [1] . Because resistance to sulfonamides has already been observed in many microorganisms, concerns have recently arisen about possible resistance in P. carinii. The target of sulfonamides is dihydropteroate synthase (DHPS). Point mutations have been observed at positions 165 (A/G) and 171 (C/T) in the human-derived P. carinii DHPS gene [2, 3] . These changes lead to amino-acid substitutions (Thr55/Ala and Pro57/Ser) in highly conserved regions in the sulfa-binding site and are homologous to mutations associated with sulfa drug resistance in bacteria and protozoa [2] . Clinical investigations further indicated that the presence of these point mutations in the P. carinii DHPS gene might be associated with impaired prognosis of PCP [4] and that they correlated with previous administration of sulfa drugs [5, 6] . These results suggested the emergence of sulfa-resistant strains of human-derived P. carinii. Because human-derived P. carinii cannot be cultured ef ciently in vitro, direct testing of the drug sensitivity of organisms has not been possible [1] .
In this study, the DHPS gene from P. carinii biotypes infecting non-human primates was ampli ed by PCR and sequenced in order to determine the prevalence of point mutations at positions 165 and 171. Non-human primatederived P. carinii organisms are closely related to human-derived P. carinii [7, 8] but do not seem to infect humans. They provided a valuable control population as none of the simian species has been exposed to sulfa drugs.
Materials and methods
A total of 94 post-mortem lung tissue samples from 32 different prosimian (lemur) or simian (monkey) species was obtained from several French zoological parks. The lung tissues were frozen after necropsy examination and stored at ¡20 o C prior to examination. After a phenolchloroform DNA extraction, a portion of the P. carinii Negative controls were included in each experiment, in both DNA extraction and PCR ampli cation, to monitor for possible contamination. Ampli cation products were puri ed in a 2% agarose gel (Trisborate EDTA buffer) and extracted with Geneclean II kit (Ozyme, Saint Quentin, France) when non-speci c bands were detected. Ampli cation products were sequenced directly from both ends using sets of internal primers on an automated DNA sequencer (Genome Express, Montreuil, France). Nucleotide and derived amino acid sequences were aligned and compared with DHPS sequences of other P. carinii organisms using the computer program CLUSTAL X (version 1.63b, December 1997) [9] . The DHPS sequence of P. carinii f. sp. hominis was retrieved from GenBank (Accession no. U66282). The DHPS sequence of P. carinii from the New World primate species Aotus nancymai (Owl monkey) was published by Beard et al. [10] .
Fischer's exact probability tests were made using Epi Info 2000 software (version 1.1.2) to compare DHPS mutation rates previously reported in P. carinii f. sp. hominis populations with that we obtained in P. carinii biotypes from non-human primates.
Results and discussion
A positive P. carinii DHPS gene ampli cation occurred with eight lung samples from ve New World primate species (one Goeldi's monkey, Callimico goeldii, two individuals of Geoffroy's marmoset, Callithrix geoffroyi, two individuals of Weddell's tamarin, Saguinus fuscicolis, one red-handed tamarin, Saguinus midas midas, and one squirrel monkey, Saimiri sciureus) and one Old World primate species (one swamp guenon, Allenopithecus nigroviridis). Direct sequencing demonstrated that a speci c P. carinii DHPS sequence could be attributed to each simian species. The sequences were assigned the GenBank Accession nos AF362758 (P. carinii from Callithrix geoffroyi), AF362760 (P. carinii from Callimico goeldii), AF362761 (P. carinii from Saguinus fuscicolis), AF362762 (P. carinii from Saguinus midas midas), AF362759 (P. carinii from Saimiri sciureus) and AF362757 (P. carinii from Allenopithecus nigroviridis). The DHPS aligned sequences comprised 625 positions. They were coding sequences and no gap was introduced for alignment (Fig. 1) . The sequence of human-derived P. carinii (GenBank Accession no. U66282) was never observed but all primate-derived P. carinii DHPS nucleotide and amino acid sequences were closely related. Furthermore, genetic divergence among primate-derived P. carinii biotypes varied in proportion to the degree of phylogenetic divergence among the corresponding host species. This suggested co-evolution of P. carinii formae speciales and their hosts, as shown in a previous study [11] . An increase in nucleotide sequence divergence was observed between P. carinii f. sp. hominis from humans and P. carinii from progressively distant species: 10.8% divergence was found with respect to P. carinii from Allenopithecus nigroviridis, 11.1-12.5% with respect to P. carinii from New World primate species and 14.6% with respect to P. carinii f. sp. muris derived from the mouse. In a comparison of the derived amino acid sequences a similar increase of divergence was observed: 11.6% divergence between P. carinii f. sp. hominis and P. carinii from Allenopithecus nigroviridis, 13.0-15.0% divergence between P. carinii f. sp. hominis and P. carinii from New World primate species and 15.0% divergence between P. carinii f. sp. hominis and P. carinii f. sp. muris.
Positions 165 and 171 are found in a conserved region of the DHPS gene where a very low divergence rate was detected. At those positions only the wild-type sequence was observed and nucleotide substitutions A/G and C/T were not detected. In derived amino acid sequences, mutations at codons 55 and 57 were not found (Fig. 1) .
Most studies about DHPS mutations in P. carinii f. sp. hominis focused solely on the signi cant mutations at codons 55 and 57. Huang et al. [12] detected these mutations in 68.5% of P. carinii biotypes (nˆ111) from patients living in three cities in the USA. In a prospective study, the same mutations were found in 71.3% of P. carinii biotypes (nˆ136) from HIV-infected patients from two geographic regions in the USA [13] , and in 20.4% of P. carinii biotypes (nˆ152) from human bronchoalveolar uids examined in Denmark [14] . Fischer's exact probability tests showed that P. carinii biotypes from non-human primates exhibited a signicantly lower rate of DHPS mutations than those reported in at least two of the three surveyed P. carinii f. sp. hominis populations (P 5 0.001 considering the two studies conducted in the USA [12, 13] , but the insigni cant Pˆ0.17 considering the study from Denmark [14] ). Of course, the arduousness of obtaining large sample sizes of monkey and lemur P. carinii places a profound constraint upon such evaluations.
Only one study of 152 human bronchoalveolar lavage samples reported just a single patient with a P. carinii biotype mutated at codon 60 in DHPS gene, whereas there were 121 samples positive for wild type P. carinii and 30 positive for mutations at codons 55 and/or 57 [14] . Mutation at codon 60 was not observed in our study except in the P. carinii sequence from the New World primate Saimiri sciureus (Fig. 1) . However, there is no reason to suspect that this mutation may be implicated in sulfa drug resistance.
As only direct sequencing was used in this study, the possibility of coinfections with DHPS wild and mutant Pneumocystis organisms in the examined lung samples could not be de nitively rejected. A predominant wildtype DHPS subpopulation might have concealed the presence of under-represented mutant-type DHPS subpopulations. Sequencing after cloning PCR products would con rm that, in the absence of prophylaxis or treatment with sulfa-containing agents, no mutations could be observed in the primate-derived P. carinii organisms.
The use of animal models would be the only way to prove that emergence of pre-existing populations with point mutations in the DHPS gene is selected by sulfa drugs administration. Pneumocystis organisms cannot be cultured, and selection trials cannot be conducted in vitro. Non-human primates represent a source of pathogens phylogenetically more related to P. carinii f. sp. hominis than rodent-derived Pneumocystis strains. As a consequence, it should be investigated whether point mutations in the DHPS gene will appear in Pneumocystis from primate populations exposed to sulfonamides. Such experimentation was rst considered by the authors but was ruled out because of its expense. The use of rodent models would be more convenient but populations of P. carinii formae speciales from rodents may not behave as P. carinii f. sp. hominis.
